Last reviewed · How we verify
Capsimax
Capsimax, developed by Laval University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Capsimax |
|---|---|
| Sponsor | Laval University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair (NA)
- A Single-Group Study to Examine the Efficacy of a Gut Health Supplement to Increase Metabolism, Improve Gut Health, and Support Weight Management (NA)
- Acute Effect of Capsimax on Resistance Exercise Performance, Muscle Oxygenation, Nitric Oxide Release, Resting Energy Expenditure and Reaction Time (NA)
- Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair (NA)
- Capsaicinoid Ingestion, Human Metabolism and Exercise (Phase 2) (NA)
- Effects of Capsimax on Appetite, Energy Intake and Blood Pressure (PHASE4)
- To Evaluate the Efficacy of Capsimax on Metabolic Rate (NA)
- Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |